Wendy S. Armstrong

Featured in: Favicon

thehill.com Favicon

healthaffairs.org Favicon

acpjournals.org Favicon

healio.com Favicon

tmc.edu

jwatch.org Favicon

lockportjournal.com

Articles

"Education of Infectious Diseases Fellows During the COVID-19 Pandemic " by Lisa M Chirch, Wendy S Armstrong et al.

Dec 5, 2024 | digitalcommons.library.tmc.edu | Wendy S. Armstrong |Prathit A. Kulkarni |Lisa M Chirch |Gayle P Balba

To view the content in your browser, please download Adobe Reader or, alternately, you may Download the file to your hard drive. NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.
Offering HOPE for Those with HIV

Oct 25, 2024 | jwatch.org | Wendy S. Armstrong

Wendy S. Armstrong, MD, reviewing Outcomes among kidney transplant recipients with HIV were similar regardless of whether the donor also had HIV. HIV infection has long been a contraindication to organ donation. Now, in an observational noninferiority study (HOPE in Action), investigators have evaluated outcomes in 198 recipients of kidney transplants who had HIV and who received organs from deceased donors with or without HIV (146 total donors).
The Continued Promise of Long-Acting Injectable Therapy for HIV Treatment

Jun 14, 2024 | jwatch.org | Wendy S. Armstrong

Wendy S. Armstrong, MD, reviewing In the African CARES trial, long-acting injectable therapy was noninferior to continued oral therapy. Long-acting injectable therapy for HIV is an important new option, but data have been lacking for settings in which prior therapy, viral subtypes, and healthcare infrastructures differ from those in high-income countries.
Strategies for Better HIV Outcomes

May 2, 2024 | jwatch.org | Wendy S. Armstrong
Updated Recommendations

Mar 12, 2024 | jwatch.org | Wendy S. Armstrong
Risk for TB-Associated IRIS in Persons with HIV on INSTI-Based Therapy

Feb 12, 2024 | jwatch.org | Wendy S. Armstrong

Wendy S. Armstrong, MD, reviewing Risk for immune reconstitution inflammatory syndrome was similar whether PWH received efavirenz- or raltegravir-based therapy. Immune reconstitution inflammatory syndrome (IRIS) develops in some persons with HIV (PWH) after they start antiretroviral therapy (ART) and is more common in those with low CD4 counts and high levels of viremia.
To End The HIV Epidemic, We Need To Reach Unsheltered Homeless Populations

Oct 20, 2023 | healthaffairs.org | Wendy S. Armstrong |Tyler Evans

Important progress has been made in the United States to increase early access to HIV care and treatment, retain individuals in care, and help individuals reach viral suppression (that is, the virus reaching a level of fewer than 200 copies of HIV per milliliter of blood). Not only does access to regular HIV care and treatment improve individual health and quality of life, but people with HIV who are virally suppressed cannot transmit HIV to other people through sex.
2023 U.S. Preventive Services Task Force Recommendation Statement

Aug 31, 2023 | jwatch.org | Wendy S. Armstrong

Wendy S. Armstrong, MD, reviewing The updated 2023 USPSTF statement recommends all antiretroviral agents approved for preexposure prophylaxis (PrEP), expanding the options for individualized therapy.
Not Ready for Broad Use

Aug 31, 2023 | jwatch.org | Wendy S. Armstrong
2023 Recommendations

Mar 9, 2023 | jwatch.org | Wendy S. Armstrong

Wendy S. Armstrong, MD, reviewing Updated DHHS guidelines emphasize shared decision making between the pregnant person living with or at risk for HIV and their care provider.